1 | per | 44,204 |
2 | days/ | 7 |
3 | stx-eq | 6 |
4 | 50,000/quality-adjusted | 5 |
5 | with-in | 5 |
6 | events/patient | 4 |
7 | ml/min/ | 4 |
8 | u/20 | 4 |
9 | -single | 3 |
10 | 100,000/quality-adjusted | 3 |
11 | at/after | 3 |
12 | mg+amoxicillin | 3 |
13 | mg/nystatin | 3 |
14 | mg/per | 3 |
15 | triclean | 3 |
16 | -rest | 2 |
17 | beats/ | 2 |
18 | cases/per | 2 |
19 | cases/person | 2 |
20 | cells/200 | 2 |
21 | counts/15 | 2 |
22 | day-hbpm | 2 |
23 | deaths/patient | 2 |
24 | episode/100 | 2 |
25 | episodes/person | 2 |
26 | events/ | 2 |
27 | infection/patient | 2 |
28 | irradiance/25 | 2 |
29 | mg/ritonavir | 2 |
30 | mg×5 | 2 |
31 | mm×0.5 | 2 |
32 | number/per | 2 |
33 | pounds/quality-adjusted | 2 |
34 | sessions/ | 2 |
35 | sugli | 2 |
36 | tdcpp/g | 2 |
37 | to75 | 2 |
38 | µg/per | 2 |
39 | 'split | 1 |
40 | +750 | 1 |
41 | -gsk2239633 | 1 |
42 | -pdtc | 1 |
43 | .paracetamol | 1 |
44 | .realized | 1 |
45 | 0.00802-0.00816 | 1 |
46 | 0.01122 | 1 |
47 | 0.15/1,000 | 1 |
48 | 0.54-1.3 | 1 |
49 | 000/quality-adjusted | 1 |
50 | 1-episode/11.1 | 1 |
51 | 1.34±2.01 | 1 |
52 | 10-59 | 1 |
53 | 12,099/additional | 1 |
54 | 12,551/rr | 1 |
55 | 1362.7/ | 1 |
56 | 13:42 | 1 |
57 | 1425.45 | 1 |
58 | 1752/100,000 | 1 |
59 | 2,558/undiscounted | 1 |
60 | 25,000/quality-adjusted | 1 |
61 | 29,665/quality-adjusted | 1 |
62 | 34.7±16.1 | 1 |
63 | 446,208 | 1 |
64 | 50,000/ | 1 |
65 | 51-550 | 1 |
66 | 51±10 | 1 |
67 | 55,090/quality-adjusted | 1 |
68 | 58.9/ | 1 |
69 | 79,391/quality-adjusted | 1 |
70 | 7x3 | 1 |
71 | 9:56 | 1 |
72 | achieved≥100 | 1 |
73 | aged≥1 | 1 |
74 | anhydroglucose | 1 |
75 | bouts/ | 1 |
76 | bw/day/2 | 1 |
77 | cg/episodes/child/academic | 1 |
78 | children/1 | 1 |
79 | conjugate-incorporated | 1 |
80 | day/5th-6th | 1 |
81 | diploria | 1 |
82 | doses/no | 1 |
83 | drv600-arm | 1 |
84 | d±2.62 | 1 |
85 | d±3.50 | 1 |
86 | edta-10 | 1 |
87 | episode/5.7 | 1 |
88 | episode/7.7 | 1 |
89 | episodes/1 | 1 |
90 | episodes/child/academic | 1 |
91 | episodes/pt/12 | 1 |
92 | evaluations/ | 1 |
93 | exacerbations/patient | 1 |
94 | failures/100 | 1 |
95 | g/drinking | 1 |
96 | g/kg/ | 1 |
97 | gesaris | 1 |
98 | grafts/ | 1 |
99 | h-cyclic | 1 |
100 | hours/per | 1 |
101 | infections/ | 1 |
102 | intake-matched | 1 |
103 | kaplicensis | 1 |
104 | koh-positive/culture-negative | 1 |
105 | mcg/kg/ | 1 |
106 | mg+cilostazol | 1 |
107 | mg/kg+npx | 1 |
108 | microg/g+/-0.03 | 1 |
109 | microg/g+/-0.41 | 1 |
110 | min/baseline | 1 |
111 | ml-plasma | 1 |
112 | mm×13.5 | 1 |
113 | monica-oberst | 1 |
114 | months,1 | 1 |
115 | months-1 | 1 |
116 | months/1 | 1 |
117 | nonintensified | 1 |
118 | nord-ovest-mammella | 1 |
119 | ofachasma | 1 |
120 | p.o.+gemcitabine | 1 |
121 | percent-57 | 1 |
122 | percent-89 | 1 |
123 | pfs/hr | 1 |
124 | physician-cancer | 1 |
125 | poisoning-a | 1 |
126 | polyetilenglicol | 1 |
127 | portions/school | 1 |
128 | posotperative | 1 |
129 | pragm | 1 |
130 | room-on | 1 |
131 | saving- | 1 |
132 | savings/patient | 1 |
133 | serves/ | 1 |
134 | servings/ | 1 |
135 | sessions/per | 1 |
136 | syn1-supplemented | 1 |
137 | tamoxifen-only | 1 |
138 | therapy/orthoptic | 1 |
139 | three-alternate | 1 |
140 | upon.the | 1 |
141 | us300,000/quality-adjusted | 1 |
142 | uti/half | 1 |
143 | violence-recent | 1 |
144 | vs.1.60±0.09 | 1 |
145 | weeks/1 | 1 |
146 | worker-family | 1 |
147 | year-old-male | 1 |
148 | year/4+ | 1 |
149 | £3.5 | 1 |
150 | µg/kg/ | 1 |
151 | μg/lng | 1 |
1 | 'split | 1 |
2 | +750 | 1 |
3 | -gsk2239633 | 1 |
4 | -pdtc | 1 |
5 | -rest | 2 |
6 | -single | 3 |
7 | .paracetamol | 1 |
8 | .realized | 1 |
9 | 0.00802-0.00816 | 1 |
10 | 0.01122 | 1 |
11 | 0.15/1,000 | 1 |
12 | 0.54-1.3 | 1 |
13 | 000/quality-adjusted | 1 |
14 | 1-episode/11.1 | 1 |
15 | 1.34±2.01 | 1 |
16 | 10-59 | 1 |
17 | 100,000/quality-adjusted | 3 |
18 | 12,099/additional | 1 |
19 | 12,551/rr | 1 |
20 | 1362.7/ | 1 |
21 | 13:42 | 1 |
22 | 1425.45 | 1 |
23 | 1752/100,000 | 1 |
24 | 2,558/undiscounted | 1 |
25 | 25,000/quality-adjusted | 1 |
26 | 29,665/quality-adjusted | 1 |
27 | 34.7±16.1 | 1 |
28 | 446,208 | 1 |
29 | 50,000/ | 1 |
30 | 50,000/quality-adjusted | 5 |
31 | 51-550 | 1 |
32 | 51±10 | 1 |
33 | 55,090/quality-adjusted | 1 |
34 | 58.9/ | 1 |
35 | 79,391/quality-adjusted | 1 |
36 | 7x3 | 1 |
37 | 9:56 | 1 |
38 | achieved≥100 | 1 |
39 | aged≥1 | 1 |
40 | anhydroglucose | 1 |
41 | at/after | 3 |
42 | beats/ | 2 |
43 | bouts/ | 1 |
44 | bw/day/2 | 1 |
45 | cases/per | 2 |
46 | cases/person | 2 |
47 | cells/200 | 2 |
48 | cg/episodes/child/academic | 1 |
49 | children/1 | 1 |
50 | conjugate-incorporated | 1 |
51 | counts/15 | 2 |
52 | day-hbpm | 2 |
53 | day/5th-6th | 1 |
54 | days/ | 7 |
55 | deaths/patient | 2 |
56 | diploria | 1 |
57 | doses/no | 1 |
58 | drv600-arm | 1 |
59 | d±2.62 | 1 |
60 | d±3.50 | 1 |
61 | edta-10 | 1 |
62 | episode/100 | 2 |
63 | episode/5.7 | 1 |
64 | episode/7.7 | 1 |
65 | episodes/1 | 1 |
66 | episodes/child/academic | 1 |
67 | episodes/person | 2 |
68 | episodes/pt/12 | 1 |
69 | evaluations/ | 1 |
70 | events/ | 2 |
71 | events/patient | 4 |
72 | exacerbations/patient | 1 |
73 | failures/100 | 1 |
74 | g/drinking | 1 |
75 | g/kg/ | 1 |
76 | gesaris | 1 |
77 | grafts/ | 1 |
78 | h-cyclic | 1 |
79 | hours/per | 1 |
80 | infection/patient | 2 |
81 | infections/ | 1 |
82 | intake-matched | 1 |
83 | irradiance/25 | 2 |
84 | kaplicensis | 1 |
85 | koh-positive/culture-negative | 1 |
86 | mcg/kg/ | 1 |
87 | mg+amoxicillin | 3 |
88 | mg+cilostazol | 1 |
89 | mg/kg+npx | 1 |
90 | mg/nystatin | 3 |
91 | mg/per | 3 |
92 | mg/ritonavir | 2 |
93 | mg×5 | 2 |
94 | microg/g+/-0.03 | 1 |
95 | microg/g+/-0.41 | 1 |
96 | min/baseline | 1 |
97 | ml-plasma | 1 |
98 | ml/min/ | 4 |
99 | mm×0.5 | 2 |
100 | mm×13.5 | 1 |
101 | monica-oberst | 1 |
102 | months,1 | 1 |
103 | months-1 | 1 |
104 | months/1 | 1 |
105 | nonintensified | 1 |
106 | nord-ovest-mammella | 1 |
107 | number/per | 2 |
108 | ofachasma | 1 |
109 | p.o.+gemcitabine | 1 |
110 | per | 44,204 |
111 | percent-57 | 1 |
112 | percent-89 | 1 |
113 | pfs/hr | 1 |
114 | physician-cancer | 1 |
115 | poisoning-a | 1 |
116 | polyetilenglicol | 1 |
117 | portions/school | 1 |
118 | posotperative | 1 |
119 | pounds/quality-adjusted | 2 |
120 | pragm | 1 |
121 | room-on | 1 |
122 | saving- | 1 |
123 | savings/patient | 1 |
124 | serves/ | 1 |
125 | servings/ | 1 |
126 | sessions/ | 2 |
127 | sessions/per | 1 |
128 | stx-eq | 6 |
129 | sugli | 2 |
130 | syn1-supplemented | 1 |
131 | tamoxifen-only | 1 |
132 | tdcpp/g | 2 |
133 | therapy/orthoptic | 1 |
134 | three-alternate | 1 |
135 | to75 | 2 |
136 | triclean | 3 |
137 | u/20 | 4 |
138 | upon.the | 1 |
139 | us300,000/quality-adjusted | 1 |
140 | uti/half | 1 |
141 | violence-recent | 1 |
142 | vs.1.60±0.09 | 1 |
143 | weeks/1 | 1 |
144 | with-in | 5 |
145 | worker-family | 1 |
146 | year-old-male | 1 |
147 | year/4+ | 1 |
148 | £3.5 | 1 |
149 | µg/kg/ | 1 |
150 | µg/per | 2 |
151 | μg/lng | 1 |
1 | year/4+ | 1 |
2 | saving- | 1 |
3 | 50,000/ | 1 |
4 | 1362.7/ | 1 |
5 | 58.9/ | 1 |
6 | g/kg/ | 1 |
7 | mcg/kg/ | 1 |
8 | µg/kg/ | 1 |
9 | ml/min/ | 4 |
10 | serves/ | 1 |
11 | servings/ | 1 |
12 | sessions/ | 2 |
13 | evaluations/ | 1 |
14 | infections/ | 1 |
15 | beats/ | 2 |
16 | grafts/ | 1 |
17 | events/ | 2 |
18 | bouts/ | 1 |
19 | days/ | 7 |
20 | 1752/100,000 | 1 |
21 | 0.15/1,000 | 1 |
22 | episode/100 | 2 |
23 | failures/100 | 1 |
24 | achieved≥100 | 1 |
25 | cells/200 | 2 |
26 | edta-10 | 1 |
27 | 51±10 | 1 |
28 | u/20 | 4 |
29 | d±3.50 | 1 |
30 | 51-550 | 1 |
31 | +750 | 1 |
32 | months,1 | 1 |
33 | months-1 | 1 |
34 | 1-episode/11.1 | 1 |
35 | 34.7±16.1 | 1 |
36 | children/1 | 1 |
37 | episodes/1 | 1 |
38 | months/1 | 1 |
39 | weeks/1 | 1 |
40 | 1.34±2.01 | 1 |
41 | microg/g+/-0.41 | 1 |
42 | aged≥1 | 1 |
43 | bw/day/2 | 1 |
44 | episodes/pt/12 | 1 |
45 | 0.01122 | 1 |
46 | 13:42 | 1 |
47 | d±2.62 | 1 |
48 | 0.54-1.3 | 1 |
49 | microg/g+/-0.03 | 1 |
50 | -gsk2239633 | 1 |
51 | 7x3 | 1 |
52 | mm×0.5 | 2 |
53 | mm×13.5 | 1 |
54 | £3.5 | 1 |
55 | counts/15 | 2 |
56 | irradiance/25 | 2 |
57 | 1425.45 | 1 |
58 | to75 | 2 |
59 | mg×5 | 2 |
60 | 0.00802-0.00816 | 1 |
61 | 9:56 | 1 |
62 | episode/5.7 | 1 |
63 | episode/7.7 | 1 |
64 | percent-57 | 1 |
65 | 446,208 | 1 |
66 | vs.1.60±0.09 | 1 |
67 | 10-59 | 1 |
68 | percent-89 | 1 |
69 | poisoning-a | 1 |
70 | diploria | 1 |
71 | nord-ovest-mammella | 1 |
72 | ofachasma | 1 |
73 | ml-plasma | 1 |
74 | h-cyclic | 1 |
75 | episodes/child/academic | 1 |
76 | cg/episodes/child/academic | 1 |
77 | therapy/orthoptic | 1 |
78 | -pdtc | 1 |
79 | intake-matched | 1 |
80 | nonintensified | 1 |
81 | conjugate-incorporated | 1 |
82 | syn1-supplemented | 1 |
83 | 2,558/undiscounted | 1 |
84 | 000/quality-adjusted | 1 |
85 | 100,000/quality-adjusted | 3 |
86 | us300,000/quality-adjusted | 1 |
87 | 50,000/quality-adjusted | 5 |
88 | 25,000/quality-adjusted | 1 |
89 | 55,090/quality-adjusted | 1 |
90 | 79,391/quality-adjusted | 1 |
91 | 29,665/quality-adjusted | 1 |
92 | pounds/quality-adjusted | 2 |
93 | .realized | 1 |
94 | upon.the | 1 |
95 | year-old-male | 1 |
96 | -single | 3 |
97 | p.o.+gemcitabine | 1 |
98 | min/baseline | 1 |
99 | anhydroglucose | 1 |
100 | three-alternate | 1 |
101 | koh-positive/culture-negative | 1 |
102 | posotperative | 1 |
103 | uti/half | 1 |
104 | tdcpp/g | 2 |
105 | g/drinking | 1 |
106 | μg/lng | 1 |
107 | day/5th-6th | 1 |
108 | sugli | 2 |
109 | 12,099/additional | 1 |
110 | polyetilenglicol | 1 |
111 | .paracetamol | 1 |
112 | portions/school | 1 |
113 | mg+cilostazol | 1 |
114 | pragm | 1 |
115 | day-hbpm | 2 |
116 | drv600-arm | 1 |
117 | triclean | 3 |
118 | with-in | 5 |
119 | mg+amoxicillin | 3 |
120 | mg/nystatin | 3 |
121 | room-on | 1 |
122 | episodes/person | 2 |
123 | cases/person | 2 |
124 | doses/no | 1 |
125 | stx-eq | 6 |
126 | physician-cancer | 1 |
127 | per | 44,204 |
128 | mg/per | 3 |
129 | µg/per | 2 |
130 | number/per | 2 |
131 | cases/per | 2 |
132 | sessions/per | 1 |
133 | hours/per | 1 |
134 | at/after | 3 |
135 | pfs/hr | 1 |
136 | mg/ritonavir | 2 |
137 | 12,551/rr | 1 |
138 | gesaris | 1 |
139 | kaplicensis | 1 |
140 | 'split | 1 |
141 | violence-recent | 1 |
142 | infection/patient | 2 |
143 | savings/patient | 1 |
144 | deaths/patient | 2 |
145 | exacerbations/patient | 1 |
146 | events/patient | 4 |
147 | -rest | 2 |
148 | monica-oberst | 1 |
149 | mg/kg+npx | 1 |
150 | worker-family | 1 |
151 | tamoxifen-only | 1 |